Condition: Netherton Syndrome · Sponsor: BioCryst Pharmaceuticals
This is a first-in-human, Phase 1/1b, 4-part study that includes the evaluation of safety, tolerability, pharmacokinetics (PK), and immunogenicity of BCX17725 when administered via single and multiple doses in healthy adult participants (Parts 1 and 2), and multiple doses in adult participants with Netherton syndrome (Part 3). In Part 4, the effectiveness, safety, and tolerability of BCX17725 when administered via multiple IV and/or SC doses through 12 weeks will be evaluated in adult and adolescent participants with Netherton syndrome.
This description comes directly from the study's public registry record.
BioCryst Pharmaceuticals, Inc. · +1 919 859 1302 · clinicaltrials@biocryst.com
Always discuss trial participation with your own doctor first.
| Stanford University School of Medicine | Palo Alto, California, United States | Not Yet Recruiting |
| Therapeutics Clinical Research | San Diego, California, United States | Recruiting |
| Yale Center for Clinical Investigation | New Haven, Connecticut, United States | Recruiting |
| Northwestern Dermatology CTU | Chicago, Illinois, United States | Recruiting |
| Dawes Fretzin Clinical Research Group, LLC | Indianapolis, Indiana, United States | Recruiting |
| Westmead Hospital - Department of Dermatology | Sydney, New South Wales, Australia | Recruiting |
| Nucleus Network | Brisbane, Queensland, Australia | Completed |
| Veracity Clinical Research | Brisbane, Queensland, Australia | Recruiting |
| Hôpital Saint-Louis | Paris, France | Recruiting |
| Universitätsklinikum Heidelberg | Heidelberg, Germany | Not Yet Recruiting |
| Maastricht Universitair Medisch Centrum (MUMC+) | Maastricht, Netherlands | Recruiting |
| Erasmus Universitair Medisch Centrum (EMC) | Rotterdam, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06539507